November 2022

Prof. Dr. rer. nat. Helga Maria Schmetzer (Dipl. Biol.)

MODIBLAST relevant publication list

I. Original publications

31. H. Salih, C. Burke, G. Starling, R. Dunn, R. Pelka-Fleischer, V. Nuessler, P. Kiener, H. M. Schmetzer: **Soluble CD137 (4-1BBL) is released following leukocyte activation and is found in sera of patients with hematological malignancies**. J. Immun. 167, 4059-4066 (2001)

34. H. Salih, V. Nuessler, C. Denzlinger, G. Starling, P. Kiener, H. M. Schmetzer: **Serum levels of CD137 ligand and CD178 are prognostic factors for progression of Myelodysplastic Syndrome.** Leukemia and Lymphoma. 45, 2, 301-308 (2004)

35. M. Graf, K. Hecht, S. Reif, R. Pelka-Fleischer, K. Pfister, H. M. Schmetzer: **Expression and prognostic value of hemopoietic cytokine receptors in Acute Myeloid Leukemia (AML): Implications for future therapeutical strategies**. Eur. J. Haematol. 72, 1-18 (2004)

38. S. Kufner, H. Zitzelsberger, T. Kroell, R. Pelka-Fleischer, A. Salem, F. de Valle, C. Schweiger, V. Nuessler, C. Schmid, H. J. Kolb, H. M. Schmetzer: **Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukemia: A methodological approach under serum-free culture conditions**. Scand J. Immunol. 62, 86-98 (2005)

39. M. Graf, S. Reif, K. Hecht, R. Pelka-Fleischer, T. Kroell, K. Pfister, H. M. Schmetzer: **High expression of costimulatory molecules correlattes with low relapse-free survival probability in Acute Myeloid Leukemia (AML).** Annals of Hematology 84, 287-297 (2005)

40. S. Kufner, H. Zitzelsberger, T. Kroell, R. Pelka-Fleischer, A. Salem, F. de Valle, C. Schmid, C. Schweiger, H. J. Kolb, H. M. Schmetzer: **Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: A methodological approach under serum-free culture conditions.** Scand J. Immunol. 62, 75-85 (2005)

42. S. Kufner, R. Pelka-Fleischer, T. Kroell, C. Schmid, H. Zitzelsberger, H. Salih, F. de Valle, W. Treder, H. M. Schmetzer: **Serum-free generation and quantification of functionally active leukemia-derived dendritic cells is possible from malignant blasts in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).** Cancer Immunol. Immunother. 54, 953-970 (2005)

44. N. Hentschel, M. Krusch, A. Kiener, H. J. Kolb, H.R. Salih, H. M. Schmetzer: **Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in Acute Myeloid Leukemia but not in non-Hodgkin's lymphoma.** Eur. J. Hematology 77, 91-101 (2006)

47. A. Kremser, J. Loibl, T. Kroell, H. J. Kolb, H. M. Schmetzer: **Quantification of ex vivo Generated Dendritic Cells (DC) and Leukemia-Derived DC ('DCleu') Contributes to Estimate the Quality of DC, to Detect Optimal DC-Generating Methods or to Optimize DC-Mediated T-Cell-Activation-Procedures ex vivo or in vivo**. Leukemia 21, 1338-1341 (2007)

48. H. M. Schmetzer: **Akute myeloische Leukämie: Vakzinierung mit dendritischen Zellen soll Rezidivrate senken**. Info-Onkologie 10, 7, 506-507 (2007)

49. H. M. Schmetzer: **Noch ist unklar, ob diese Immuntherapie wirksam ist**. Kommentar zum Artikel von Roddie et al. Br J. Haematology 2006. Info-Onkologie 10, 7, 507-508 (2007)

50. H. M. Schmetzer: **Dendritic cells as Prognostic Indicators or as Immunotherapeutic Tools to Treat Acute Myeloid Leukemia (AML) and High-Grade Myelodysplasia (MDS). Review.** Recent advances and Research Updates 9, 1, 125-137 (2008) (invited publication, award as eminent scientist of the year (2007)

52. F. Schuster, R. Buhmann, S. Reuther, B. Hubner, C. Grabrucker, A. Liepert, R. Reibke, P. Lichtner, T. Yang, T. Kroell, H. J. Kolb, A. Borkhardt, H. M. Schmetzer: **Improved effector functions of leukaemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.** Cancer Genomics Proteomics 5, 275-286 (2008)

54. N. Scholl, J. Loibl, A. Kremser, A. Liepert, C. Grabrucker, H. R. Salih, H. J. Kolb, H. M. Schmetzer**: The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoetic disorders**. Leukemia Lymphoma 50, 3, 427-436 (2009)

55. A. Kremser, J. Dreyssig, C. Grabrucker, A. Liepert, T. Kroell, N. Scholl, C. Schmid, J. Tischer, S. Kufner, H. Salih, H. J. Kolb, H. M. Schmetzer: **Dendritic cells can be successfully generated from leukemic blasts in individual patients with AML or MDS**. J. Immunotherapy 33, 185-199 (2010)

56. C. Grabrucker, A. Liepert, J. Dreyssig, A. Kremser , T. Kroell ,M. Freudenreich , C. Schmid, C. Schweiger, J. Tischer, H. J. Kolb, H. M. Schmetzer: **The quality and quantity of leukemia-derived Dendritic cells (dc) from patients with acute myeloid leukemia and myelodysplastic syndrom are a predictive factor for the lytic potential of DC-primed leukaemia-specific T-cells.** J. Immunotherapy 33, 5, 523-537 (2010)

57. D. Bund, R. Buhmann, F. Gökmen, A. Kremser, J. Dreyßig, H. J. Kolb, H. M. Schmetzer: **Canine-DCs using different serum-free methods as an approach to provide an animal model for immunotherapeutic strategies.** H. J. Kolb and H. M. Schmetzer contributed equally) Cellular Immunology 263, 88-98 (2010)

59. A. Liepert, C. Grabrucker, A. Kremser, J. Dreyssig, C. Ansprenger, M. Freudenreich, T. Kroell, R. Reibke, J. Tischer, C. Schweiger, C. Schmid, H. J. Kolb, H. M. Schmetzer: **Quality of T-cells after Stimulation with Leukemia-derived Dendritic cells (DC) from Patients with Acute Myeloid Leukemia (AML) or Myeloid Dysplastic Syndrome (MDS) is predictive for their leukemia cytotoxic potential.** Cellular Immunology 265, 23-30 (2010)

60. B. Wöhrl, M. Klein, T. Rupprecht, H. M. Schmetzer B. Angele, H. Haecker, G. Haecker, H. W. Pfister, U. Koedel: **CXCL16 contributes to neutrophil recruitment to the CSF in pneumococcal meningitis.** Journal of Infectious Diseases 1, 202(9), 1389-1396 (2010)

62. H. M. Schmetzer: **Antileukemic T-cell-mediated immune reactions: limitations and perspectives for future therapies.** Immunotherapy 3, 7, 809-811 (2011)

63. J. Dreyßig, A. Kremser, A. Liepert, C. Grabrucker, M. Freudenreich, C. Schmid, T. Kroell, N. Scholl, J. Tischer, S. Kufner, H. Salih, H. J. Kolb, H. M. Schmetzer: **Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.** Immunotherapy 3, 9, 1113-1124 (2011)

65. S. Reuther, F. Schuster, P. Krell, C. Grabrucker, A. Liepert, T. Kroell, H. J. Kolb, A. Borkhardt, R. Buhmann, H. M. Schmetzer: **In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping.** (H. Schmetzer and S. Reuther contributed equally) Clin. Exp. Med. 13, 1, 29-48, (2013)

67. J. Schick, V. Vogt, M. Zerwes, T. Kroell, C. Schweiger, D. Kraemer, C. H. Köhne, A. Hausmann, R. Buhmann, J. Tischer, H. M. Schmetzer: **Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.** J. Immunotherapy 36, 4, 223-237 (2013)

68. A. Kremser, S. Kufner, E. Konhaeuser, T. Kroell, A. Hausmann, J. Tischer, H. J. Kolb, H. Zitzelsberger, H. M. Schmetzer: **Combined immunophenotyping and fluorescence in situ hybridization with chromosome-specific DNA probes allows quantification and differentation of ex vivo generated dendritic cells, leukemia-derived dendritic cells, and clonal leukemic cells in patients with acute myeloid leukemia.** Leuk. Lymphoma 54, 6, 1297-308 (2013)

69. B. Steger, S. Milosevic, G. Doessinger, S. Reuther, A. Liepert, M. Braeu, J. Schick, V. Vogt, F. Schuster, T. Kröll, D. H. Busch, A. Borkhardt, H. J. Kolb, J. Tischer, R. Buhmann, H. M. Schmetzer: **CD4+ and CD8+ T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML- patients after allogeneic SCT.** Immunobiology 219, 247-260 (2014)

71. V. Vogt, J. Schick, C. Ansprenger, M. Braeu, T. Kröll, D. Krämer, C.-H. Köhne, A. Hausmann, A. Hausmann, R. Buhmann, J. Tischer, H. M. Schmetzer: **Profiles of activation, differentiation-markers, or ß-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.** J. Immunotherapy 37, 6, 331-347 (2014)

72. H. J. Kolb, H. M. Schmetzer, C. Schmid, I. Bigalke, R. Buhmann, A. Moosmann, C. Falk, S. Reuter, F. Schuster, A. Borkhardt: **Mechanisms of graft-versus-leukemia effects after allogeneic stem cell transplantation: effects on the leukemia stem cell?** Leukemia 3, 1-2, (2014)

75. L. Wahlers und H. M. Schmetzer: **Immuntherapien gegen Krebs.** Kongressbericht Immunotherapy of Cancer 2, Lukon Verlag (2015), TZM News 2 (2015)

79. J. Schmohl, T. Nuebling, J. Wild, T. Kroell, L. Kanz, H. R. Salih, H. M. Schmetzer**: Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML**. J. Investig. Md. Doi 10,1136/jim-2016-000081 (2016)

80. D. Fischbacher, M. Merle, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C.H. Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Cytokine release patterns in mixed lymphocyte culture (MLC) of T-cells with Dendritic cells (`DC`) generated from AML blasts contribute to predict anti-leukaemic T-cell reactions and patients' response to immunotherapy.** Cell Communication and Adhesiondx.doi.org/10.1080/15419061.2016.1223634 (2016)

81. C. Boeck, D. Amberger, F. Doraneh-Gard, W. Sutanto, T. Guenther, J. Schmohl, F. Schuster, H. Salih, F. Babor, A. Borkhardt, H. M. Schmetzer: **Significance of frequencies, compositions and/or antileukemic activity of (DC-stimulated) invariant NKT-, NK- and CIK-cells on the outcome of patients with AML, ALL and CLL.** Journal of Immunotherapy 40, 6, 224-248 (2017)

82. A. Dickinson, J. Norden, S. Li, I. Hromadnikova, C. Schmid, H. J. Kolb, H. M. Schmetzer: **Graft-versus-Leukaemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.** Frontiers in Immunology 8, 296, 1-16, (2017)

84. C. Ansprenger, V. Vogt, J. Schick, A. Hirn-Lopez, Y. Vokac, I. Harabacz, M. Braeu, T. Kroell, A. Karenberg, H. J. Kolb, H. M. Schmetzer: **Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells.** Cellular Immunol., 328, 33-48 (2018)

86. A. Hirn Lopez, D. Deen, Z. Fischer, A. Rabe, C. Ansprenger, K. Stein, V. Vogt, J. Schick, T. Kroell, D. Kraemer, H. J. Kolb, J. Tischer, C. Schmid, H. M. Schmetzer: **Role of interferon (ifn)α in "cocktails" for the generation of (leukemia-derived) dendritic cells (dcleu) from blasts in blood from patients (pts) with acute myeloid leukemia (aml) and the induction of antileukemic reactions** J. Immunotherapy, 42, 5, 143-161 (2019)

88. M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C. H. Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Serum chemokine-release profiles in aml-patients might contribute to predict the clinical course of the disease.** Immunol Investigations, 19:1-21. doi: 10.1080/08820139.2019.1661429. Epub ahead of print, (2019 Sep)

89. D. C. Amberger, F. Doraneh-Gard, C. Gunsilius, M. Weinmann, S. Möbius, C. Kugler, N. Rogers, C. Böck, U. Ködel, J.O. Werner, D. Krämer, D. Eiz-Vesper, A. Rank, C. Schmid, H. M. Schmetzer: **PGE1-Containing protocols generate mature (leukemia-derived) dendritic cells directly from leukemic whole blood.** Int J Mol Sci. 20, 18, 4590 (2019)

90. B. Steger, L. Floro, D. C. Amberger, T. Kroell, J. Tischer, H. J. Kolb, H. M. Schmetzer: **WT1, PRAME and PR3 mRNA Expression in Acute myeloid leukemia (AML)** J. Immunother. 43(6):204-215 (2020)

91. C. Ansprenger, D. C. Amberger, H. M. Schmetzer: **Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - with a focus on Dendritic cells of leukemic origin (DCleu)** Clin Immunology 217 (1-6) (2020)

92. D. C. Amberger, H. M. Schmetzer: **Dendritic cells of leukemic origin: specialized antigen-presenting cells as potential treatmenttools for patients with myeloid leukemia.** Transfus Med Hemother DOI: 10.1159/000512452a (2020)

93. B. Eiz-Vesper, H. M. Schmetzer: **Antigen-presenting cells: potential of proven and new players in Immunetherapies.** Transfus Med Hemother, DOI: 10.1159/000512729 (2020)

94. H. M. Schmetzer: Special Issue "**Dendritic cells—conductors and activators of the immunological orchestra"** Int J. Mol Sci
https://www.mdpi.com/journal/ijms/special_issues/leukemia_derived_DC (2020)

97. M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C. H. Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.** Immunobiology 226,152088 (2021)

98. L. Klauer, O. Schutti, S. Ugur, F. Doraneh-Gard, D. Amberger, N. Rogers, D. Kraemer, A. Rank, C. Schmid, B. Eiz-Vesper, H. M. Schmetzer: **IFNy secretion of adaptive and innate immune cells as a parameter to describe leukaemia derived dendritic cell mediated immune responses in AML in vitro.** Transfus Med Hemother in press (2021)

100. M. Freudenreich, J. Tischer, T. Kroell, A. Kremser, J. Dreyßig, C. Beibl, A. Liepert, H. Kolb, C. Schmid, H. M. Schmetzer: **In vitro generated dendritic cells of leukemic origin predict response to allogeneic stem cell transplantation in patients with AML and MDS.** J. Immunotherapy DOI: 10.1097/CJI.0000000000000404 (2021)

102. E. Pepeldjiyska, L. Li, J. Gao, C. Seidel, C. Blasi, E. Özkaya, J. Schmohl, D. Kraemer, C. Schmid, A. Rank, H. M. Schmetzer: **Leukemia derived dendritic cell (DCleu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells.** Immunobiology 227 152237 (2022)

103. C. Plett, L. Klauer, D. Amberger, S. Ugur, A. Rabe, Z. Fischer, D. Deen, A. Hirn-Lopez, C. Gunsilius, J. Werner, J. Schmohl, D. Krämer, A. Rank, C. Schmid, H. M. Schmetzer: **Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia**
Clinical Immunology 242,109083, doi.org/10.1016/j.clim.2022.109083 (2022)

104. C. Schwepcke, L. Klauer, D. Deen, D. Amberger, Z. Fischer, F. Dorenah-Gard, C. Gunsilius, A. Hirn Lopez, T. Kroell, J. Tischer, M. Weinmann, J. Werner, A. Rank, C. Schmid, H. M. Schmetzer: **Generation of leukaemia-derived dendritic cells (DC_{leu}) to improve anti-leukaemic activity in AML: Selection of the most efficient response modifier combinations**. Int J. Mol Science 23,8333, doi. org/10.3390/ijms23158333 (2022)

[cumulative MODIBLAST-related Impactfactors:177.06

MANUSCRIPTS SUBMITTED

E. Rackl, H. M. Schmetzer; **Profiles of ß-integrin-expressions on (leukemia specific) T or NK cells to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells and correlations with patients' prognosis.**

E. Rackl, H. M. Schmetzer; **Profiles of TCRyd-expressions on (leukemia specific) T cells to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells and correlations with patients' prognosis.**

MANUSCRIPTS IN PREPARATION

M. Atzler, R. Wang, M. Rabe, Z. Stankova, C. Plett, J. Schmohl, D. Krämer, M. Inngjerdingen, H. M. Schmetzer: **Immunomodulation of AML-blasts derived from patients or rat strains with clinically approved response modifiers to improve antileukemic T-cell reactivity: an ex vivo simulation of the clinical situation and in vivo treatment approach.**

F. Doranehgard, D. Amberger C. Gunsilius, C. Kugler, H. M. Schmetzer**: Influence of Hypoxia on immunoreactive processes during in a context of DC-stimulation of T-cells**

S. Ugur, L.K. Klauer, C. Blasi, F. Doraneh-Gard, C. Plett, C. Gunsilius, D.C. Amberger, M. Weinmann, O. Schutti, Z. Fischer, E. Özkaya, M. Atzler, E. Pepeldjiyska, A. Völker, J. Schmohl, A. Rank, C. Schmid, H. M. Schmetzer: **'Kit'-mediated blastmodulation to leukemia-derived DC significantly improves antileukemic activities in whole blood independent of AML-patients' subtypes.**

H. Aslan, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, T. Kroell, D. Bund, R. Buhmann, A. Hausmann, C. Schmid, J. Tischer, H. M. Schmetzer: **Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve antileukemic T-cell reactivity: an ex vivo simulation of the clinical situation.**

E. Rackl, H. M. Schmetzer; **Profiles of TCRyd--expressions on (leukemia specific) T-cells to predict T-cells' antileukemic responses after stimulation with leukemia-derived dendritic cells and correlations with patients' prognosis.**

A. Hartz, H. M. Schmetzer; **Tolerogenic DC on AML or healthy DC, their role tpo predict T-cells' antileukemic responses after stimulation with leukemia-derived dendritic cells and correlations with patients' prognosis**

Z. Fischer, A. Hirn-Lopez, H. M. Schmetzer: **Composition of T-cells, DC and the cytokine release profile are predictive for the antileukemic response of DC-stimulated T-cells** (in prep 2021)

S. Bohlscheid, E. Pepeldjiyska, L. Li, J. Gao, C. Seidel, C. Blasi, E. Özkaya, J. Schmohl, D. Kraemer, C. Schmid, A. Rank, H. M. Schmetzer: Kit-treatment of **Antileukaemic T-cell responses can be predicted by compositions of regulatory T-cell subpopulations-under hypoxic and normoxic conditions**

S. Bohlscheid, C. Schmid, H. M. Schmetzer: **Aberrant expression of CD86 on AML-blast can activate silent CTLA4pos Tcells and result in downregulation of immune responses after Allo-SCT**

C. Gunsilius, D. Amberger, F. Doranehgard C. Kugler, H. M. Schmetzer: **Checkpoint molecule expression in AML.**

M. Weinmann, D. Amberger, C. Gunsilius F. Doranehgard C. Kugler, H. M. Schmetzer: **Expression of Apoptosis-markers during DC generation from AML blasts.**

D. Deen, F. Doranehgard, H. M. Schmetzer**: Role of apoptotic marker expression on DC for the mediation of antileukemic reactions.**

O. Schutti, F. Burkert, H. M. Schmetzer: **Intracellular cytokine and Degranulations-assays as tools to monitor the production of antigenspecific IFN- γ/TNFα-producing or degranulating cells of the innate and adaptive immune system in culture systems of Tcells stimulated with leukemia-derived DC**

N. Schmieder, H. M. Schmetzer: **Monitoring of leukemia-specific cells in the clinical course allows an estimation of relapse free survival**

M. Unterfrauner, H. M. Schmetzer: **Kit-treatment of blast-containing BM and PB-cells from AML-patients give rise to DC/DCleu –resulting in improved blast-lysis after stimulation of patients' Tcells with both Kit-treated BM and PB samples**

M. Unterfrauner, D. Amberger, Y. Vokac, A. Hirn-Lopez, D. Deen, T. Kroell, C. Schmid, H.J. Kolb, J. Tischer, H. M. Schmetzer. **Released soluble factors in serum or supernatants of leukemia-derived dendritic cell or mixed lymphocyte cultures are predictive for T-cells' antileukemic functionality or clinical response to immunotherapy.**

J. Schmohl, R. Buhmann, T. Yang, C. Grabrucker, A. Liepert, A. Kremser, J. Dreyßig, T. Kroell, C. Schmid, J. Tischer, S. Kaiser, H. J. Kolb, H. M. Schmetzer: **Dendritic cells can act as amplifiers of leukaemia-lysis or leukaemia-stimulation: a contribution to a refined functional analysis of partners involved in the mediation of anti-leukemic reactions.**

L. Li, V. Mussack, H. M. Schmetzer: **Kit-treatment of leukemic blast-containing whole blood shifts release patterns of extracellular vesicle release after culture with kits as well as after MLC with patients' T-cells**

II.Contributions to books

B14. H. J. Kolb, S. Kaiser, H. M. Schmetzer, C. Schmid: **Dendritic cell-based immunotherapy of Acute Myeloid Leukemia**. Buchbeitrag, (2005)

B15. C. Schmid, H. M. Schmetzer: **The T-cells' role in antileukemic reactions-perspectives for future therapies.** Taner Demirer, InTech (IBN 978-953-5-0013-3), Part 1: 'Basic aspects of stem cell transplantation': chapter 4, 959-982 (2012)

III. Patents/TV/Interviews/Talks

1. H. M. Schmetzer**: Characterization, identification, and monitoring of T-lymphocyte populations.** Transregion 36-SFB-retreat, Herrsching, Vortrag, (2007)

2. H. M. Schmetzer: **Leukemia derived DC for T-cell therapy against leukemic progenitor cells.** GvH-GvL-International stem cell meeting, Bad Aibling, Vortrag, (2008)

3. H. J. Kolb, H. M. Schmetzer: **The composition and quality of leukemia-derived leukemia-derived DC, T-cells and the cellular microenvironment is predictive for the antileukemic T-cell cytotoxic reactions of DC-primed T-cells and the response to therapy.** XI. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Highlight-Vortrag, 61 (2009)

4. H. M. Schmetzer: Erfindungsmeldung: **Para-Immunitäts-Iinducer (PINDS) zur Immunmodulation und -therapie bei AML.** (2010)

5. J. Schick, H. M. Schmetzer: **Antileukemic T-cell responses can be predicted by compositions of regulatory T-cell subpopulations, especially with respect to regulatory effector-memory and regulatory CD8+ T-cells.** XIV. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Vortrag, 50 (2012)

6. B. Steger, H. M. Schmetzer: **CD4+ and CD8+ T-cell reactions against leukaemia-associated or minor histocompatibility antigens in AML patients after allogeneic SCT.** XIV. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Vortrag, 55 (2012)

7. H. M. Schmetzer: Erfindungsmeldung: **Immunmodulatoren für Leukämiepatienten AML.** (2013)

8. H. M. Schmetzer: Patentanmeldung (international, PCT): **Verwendung von immunmodulatorisch wikrsamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien.** Patentanmeldung eingereicht Okt (2015)

9. Gesprächssendung ‚alpha-Forum': H. M. Schmetzer (Spezialistin für Immuntherapie von Leukämien): Thema: **Symptomatik, Diagnostik und Therapie von Leukämien mit speziellem Fokus auf Immuntherapien und aktuelle Leukämieforschung.** 20.15 Uhr, ARD-alpha, (01.02.20217)

10. H. M. Schmetzer (übertragen auf: MODIBLAST GMBH): Erteilung Deutsches Patent: **Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien.** Patent DE 10 2014 014 993.5, (2017)

11. Vortrag in der BioM: ImmPact Matchworking event', H. M. Schmetzer: **Immunomodulation ofaml-blasts with clinically approved response modifiers improves antileukemic T-cell reactivity and leads to blast-reduction ex vivo and in vivo** (3. März 2017)

12. Vortrag im Universitätsklinikum Augsburg', H. M. Schmetzer: **Immunomodulation of AML-blasts with clinically approved response modifiers improves antileukemic T-cell reactivity and leads to blast-reduction ex vivo and in vivo** 25.4. (2017)

13. H. M. Schmetzer: Vortrag an der MHH Hannover: **Immunomodulation of AML blasts improves anti-leukemic reactivity ex vivo and in vivo** 22.12. (2017)

14. H. M. Schmetzer (übertragen auf: MODIBLAST GMBH): Erteilung Europäisches Patent: **Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien.** Patent 3217975, (2019)

15. H. M. Schmetzer (übertragen auf: MODIBLAST GMBH): Erteilung amerikanisches Patent: **Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien.** Patent US 15-517627, (2020)

IV. Contributions to congresses (Talks und Posters)

81. H. M. Schmetzer, R. Pelka-Fleischer, T. Kroell, W. Hiddemann, V. Nuessler: **Dendritic cells in AML and MDS – comparison of different FCS-free culture conditions**. Eur. J. Cancer 37, suppl. 3, abstract 66 (2001)

86. H. M. Schmetzer, R. Pelka-Fleischer, T. Kröll, W. Hiddemann, V. Nüssler: **Dendritic cell generation in AML and MDS – comparison of different FCS-free culture conditions**. Onkologie 24, suppl. 6, abstract 517 (2001)

88. M. Graf, S. Danhauser-Riedl, S. Reif, C. Schoch, S. Schnittger, T. Haferlach, K. Pfister, W. Hiddemann, V. Nuessler, H. M. Schmetzer**: Expression of adhesion molecules and costimulatory antigens in acute myeloid leukemia**. Annual meeting of the American Society of Hematology, Blood 98, 11, abstract 4445 (2001)

90. H. M. Schmetzer, R. Pelka.Fleischer, T. Kroell, F. de Valle, T. Haferlach, W. Kern, C. Schoch, K. Doehner, W. Hiddemann, V. Nussler: **Different autologous/allogeneic T-cell activation of dendritic cells from MDS and AML.** Onkologie 25, abstract 641 (2002)

92. H. M. Schmetzer, R. Pelka.Fleischer, T. Kroell, F. de Valle, T. Haferlach, W. Kern, C. Schoch, K. Doehner, W. Hiddemann, V. Nussler: **Different autologous/allogeneic T-cell activation of dendritic cells from MDS and AML.** Annual meeting of the American Society of Hematology, Blood 100, 11, abstract 4522 (2002)

94. S. Kufner, A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, V. Nuessler, C. Schoch, K. Doehner, T. Haferlach, W. Hiddemann, H. M. Schmetzer: **Generation and characterization of leukemia-derived dendritic cells (DC) in AML and MDS after contact with autologous or allogeneic T-cells.** V. wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 16 (2003)

95. S. Kufner, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, V. Nuessler, W. Kern, K. Doehner, T. Haferlach, E. Thiel, W. Hiddemann, H. M. Schmetzer: **Generation and characterization of dendritic cells (DC) from mononuclear cells in AML and MDS.** 7th International Meeting and 1st World Congress Biotherapy of Cancer, Munich, (2003)

96. A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, I. Zirpel, C. Schoch, V. Nuessler, W. Kern, T. Haferlach, K. Doehner, E. Thiel, W. Hiddemann, H. M. Schmetzer: **Phenotypic and functional characterization of autologous or allogeneic T-cells after contact with leukemia-derived dendritic cells (DC) in AML and MDS in mixed lymphocyte reactions.** 7th International Meeting and 1st World Congress Biotherapy of Cancer, Munich, (2003)

97. S. Kufner, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, V. Nuessler, W. Kern, K. Doehner, T. Haferlach, E. Thiel, W. Hiddemann, H. M. Schmetzer: **Generation and characterization of dendritic cells from mononuclear cells in AML and MDS.** Onkologie 26, Sonderheft 5, 220 (2003)

98. A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, I. Zirpel, C. Schoch, V. Nuessler, W. Kern, T. Haferlach, K. Doehner, E. Thiel, W. Hiddemann, H. M. Schmetzer: **Phenotypic and functional characterization of autologous or allogeneic T-cells after contact with leukemia-derived dendritic cells (DC) in AML and MDS in mixed lymphocyte reactions.** Onkologie 26, Sonderheft 5, 220 (2003)

99. H. M. Schmetzer, S. Kufner, A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, W. Hiddemann, V. Nuessler: **Generation and characterization of leukemia-derived Dendritic cells (dc) in AML and MDS after contact with autologous or allogeneic t-cells.** Blood 102, 11, abstract 4713, (16.11.2003)

100. S. Kufner, A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, V. Nuessler, C. Schoch, K. Doehner, T. Haferlach, W. Hiddemann, H. M. Schmetzer: **Generation and characterization of leukemia-derived dendritic cells (DC) in AML and MDS after contact with autologous or allogeneic T-cells.** VI. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 28 (2004)

101. H. M. Schmetzer, S. Kufner, A. Salem, T. Kroell, R. Pelka-Fleischer, F. de Valle, H. Zitzelsberger, I. Zirpel, W. Hiddemann, V. Nuessler: **Generation and Characterization of Leukemia-Derived Dendritic Cells (DC) in AML and MDS after Contact with Autologous or Allogeneic T-Cells.** Ann. Hemat. 83, 1, 17 (2004)

102. H. M. Schmetzer, C. Schmid, S. Kufner, R. Pelka-Fleischer, T. Kroell, H. Zitzelsberger, W. Treder, H.J. Kolb: **Generation of leukemia-derived dendritic cells (dcleu) as a basis for specific immunotherapy in acute myeloid leukemia and myelodysplasia.** Blood 104, 11, abstract 2547, (2004)

103. A. Kremser, J. Loibl, T. Kroell, S. Kufner, R. Pelka-Fleischer, H. Salih, C. Schmid, T. Haferlach, W. Kern, C. Schoch, F. de Valle, C. Doehner, C. Schweiger, E. Thiel, W. Hiddemann, H.J. Kolb, H. M. Schmetzer**: Leukemia-derived DC can be generated and quantified in every patient with AML or MDS using 3 alternative methods in combination.** VII. Wissenschaftliches Symposium der Medizinischen Klinik III, Bad Irsee, 38 (2005)

104. H. M. Schmetzer, A. Kremser, J. Loibl, T. Kroell, S. Kufner, R. Pelka-Fleischer, H. Salih, C. Schmid, T. Haferlach, W. Kern, C. Schoch, F. de Valle, C. Doehner, C. Schweiger, E. Thiel, W. Hiddemann, H. J. Kolb: **Leukemia-derived DC can be generated in every patient with AML or MDS using 3 alternative methods in combination, however a detailed analysis of the marker profiles of DC is necessary to quantify leukaemia-derived DC.** VII. Wissenschaftliches Symposium der Medizinischen Klinik III, Bad Irsee, 63 (2005)

105. J. Loibl, A. Kremser, T. Kroell, C. Schmid, S. Kufner, C. Schweiger, F. de Valle, W. Kern, C. Schoch, T. Haferlach, C. Doehner, E. Thiel, H.J. Kolb, H. M. Schmetzer**: Dendritic cell marker expression profiles have to be evaluated before and after the generation of DC from blasts in AML and MDS to characterize and quantify DC in individual experimental settings.** VII. Wissenschaftliches Symposium der Medizinischen Klinik III, Bad Irsee, 44 (2005)

107. A. Kremser, J. Loibl, T. Kroell, S. Kufner, R. Pelka-Fleischer, H. Salih, C. Schmid, T. Haferlach, W. Kern C. Schoch, F. de Valle, C. Doehner, C. Schweiger, E. Thiel, W. Hiddemann, H. J. Kolb, H. M. Schmetzer**: Leukemia-derived DC can be generated and quantified in every patient with AML or MDS using 3 alternative methods in combination.** Onkologie 28, suppl. 3, abstract 360, (2005)

108. H. M. Schmetzer, A. Kremser, J. Loibl, T. Kroell, S. Kufner, R. Pelka-Fleischer, H. Salih, C. Schmid, T. Haferlach, W. Kern, C. Schoch, F. de Valle, C. Doehner, C. Schweiger, E. Thiel, W. Hiddemann, H. J. Kolb: **Leukemia-derived DC can be generated in every patient with AML or MDS using 3 alternative methods in combination, however a detailed analysis of the**

marker profiles of DC is necessary to quantify leukaemia-derived DC. Onkologie 28, suppl. 3, abstract 361, (2005)

109. J. Loibl, A. Kremser, T. Kroell, C. Schmid, S. Kufner, C. Schweiger, F. de Valle, W. Kern, C. Schoch, T. Haferlach, C. Doehner, E. Thiel, HJ Kolb, H. M. Schmetzer**: Dendritic cell marker expression profiles have to be evaluated before and after the generation of DC from blasts in AML and MDS to characterize and quantify DC in individual experimental settings.** Onkologie 28, suppl. 3, abstract 358, (2005)

111. H. M. Schmetzer, A. Kremser, J. Loibl, N. Hentschel, K. Steiner, C. Schmid, T. Kroell, S. Kufner, H. Salih, F. Delvalle, C. Doehner, C. Schweiger, C. Schwartz, W. Hiddemann, H. J. Kolb: **Effective ex vivo generation and quantification of leukemia-derived DC has to precede a specific T-cell stimulation for adoptive immunotherapy in AML and MDS.** Blood 106, 1, abstract 5241, (2005)

113. H. M. Schmetzer, A. Kremser, J. Loibl, C. Grabrucker, A. Liepert, N. Hentschel, S. Kaiser, T. Kroell, S. Kufner, H. Salih, C. Schmid, J. Tischer, F. de Valle, C. Doehner, W. Treder, S. Schwartz, H. Zitzelsberger, W. Hiddemann, H. J. Kolb: **Generability and quality of leukaemia-derived DC in AML or MDS: conditions and consequences.** Bone Marrow Transplantation 37, suppl. 1, P404, 69 (2006)

114. J. Loibl, A. Kremser, T. Kroell, S. Kufner, H. Zitzelsberger, C. Schmid, C. Schweiger, F. de Valle, W. Kern, C. Schoch, T. Haferlach, C. Doehner, E. Thiel, H. J. Kolb, H. M. Schmetzer: **Dendritic cell antigen (DCA) expression profiles have to be evaluated before and after the generation of DC from blasts in acute myeloid leukemia and myelodysplastic syndrome to characterize and quantify DC in individual experimental settings.** VIII. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 48 (2006)

115. A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, N. Hentschel, T. Kroell, R. Buhmann, T. Yang, S. Kaiser, C. Schmid, J. Tischer, H. Zitzelsberger, H. J. Kolb, H. M. Schmetzer**: Leukemia-derived Dendritic cells (Dcleu) are stronger stimulators of T-cells than blasts and give rise to Memory T-cells and Leukemia-cytotoxic T-cells.** VIII. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 46 (2006)

116. C. Grabrucker, A. Liepert, A. Kremser, M. Freudenreich, J. Loibl, N. Hentschel, T. Kroell, W. Kern, C. Schoch, T. Haferlach, C. Doehner, E. Thiel, C. Schmid, J. Tischer, H. Zitzelsberger, H. J. Kolb, H. M. Schmetzer**: Leukemia-derived Dendritic cells (Dcleu) can be generated in every case of AML and MDS using 3 alternative culture methods in combination, they can be used to stimulate T-cells and are possibly predictive for the clinical response to a DLI/GM-CSF-based (prophylactic) therapy.** VIII. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 32 (2006)

117. H. J. Kolb, R. Buhmann, H. M. Schmetzer**: Overview: Immunotherapeutic strategies in allogeneic stem cell transplantation.** VIII. Wissenschaftliches Symposium der Medizinischen Klinik III (Übersichtsvortrag), Herrsching (2006)

118. H. M. Schmetzer, C. Grabrucker, A. Liepert, A. Kremser, J. Loibl, C. Schmid, R. Buhmann, T. Yang, T. Kroell, H. Salih, H. Zitzelsberger, H.J. Kolb: **A step towards reconstitution or maintenance of remission before or after stem cell transplantation in AML/MDS by ex vivo generation of leukemia-derived DC (DCleu) and DC-activated T-cells: Role of the**

quality and quantity of DC/DCleu and anti-leukemia-directed T-cells to predict the course and success of immunotherapy. Blood 108, 1, abstract 3246, 11 (2006)

119. H. M. Schmetzer, A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, C. Schmid, R. Buhmann, T. Yang, T. Kroell, F. Del Valle, W. Treder, H. J. Kolb: **Role of the quality andf quantity of leukemia-derived dendritic cells and anti-leukemia-directed T-cells to predict the course and success of immunotherapy.** Bone Marrow Transplantation 39, 1, O302, (2007)

120. A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, C. Schmid, R. Buhmann, T. Yang, T. Kroell, F. Del Valle, W. Treder, H. J. Kolb, H. M. Schmetzer: **A successful anti-leukemic cytotoxic reaction depends on at least two partners: elucidation of the role of leukemia-derived DC and anti-leukemia-directed T-cells.** Bone Marrow Transplantation 39, 1, P764, (2007)

121. H. M. Schmetzer**: Characterization, identification, and monitoring of T-lymphocyte populations.** Transregio 36-SFB-retreat, Herrsching, Vortrag, (2007)

122. H. M. Schmetzer, C. Grabrucker, A. Liepert, A. Kremser, J. Loibl, M. Freudenreich, R. Reibke, R. Buhmann, T. Yang, C. Schmid, T. Kroell, H. J. Kolb: **Quality of leukemia-derived dendritic cells (DC) and T-cells are predictive for the specific anti-leukemic potential of DC-trained T-cells.** Blood 110, 11, abstract 4883, (2007)

125. H. M. Schmetzer: **Leukemia Derived DC for T-cell Therapy against Leukemic Progenitor Cells.** GvH-GvL-International stem cell meeting, Bad Aibling, Vortrag, (2008)

126. H. M. Schmetzer, C. Grabrucker, A. Liepert, A. Kremser, J. Loibl, M. Freudenreich, R. Reibke, R. Buhmann, T. Yang, C. Schmid, T. Kroell, H. J. Kolb: **Dendritic cells as prognostic indicators or immunotherapeutic tools to treat acute myeloid leukemia: role of the quality of leukemia-derived DC to predict the specific anti-leukemic potential of (DC-trained) T-cells.** Bone Marrow Transplantation 41, 1, P642, (2008)

127. H. M. Schmetzer, C. Grabrucker, A. Liepert, A. Kremser, J. Loibl, M. Freudenreich, R. Reibke, R. Buhmann, T. Yang, C. Schmid, T. Kroell, H. J. Kolb: **Dendritic cells as prognostic indicators or immunotherapeutic tools to treat acute myeloid leukemia: role of the quality of leukemia-derived DC to predict the specific anti-leukemic potential of (DC-trained) T-cells.** Haematologica 93, suppl. 1, P0594, (2008)

128. S. Reuther, H. M. Schmetzer, A. Borkhardt, F. Schuster: **Characterization of leukemia specific T-cell clones trained with AML-derived dendritic cells shows a restricted t-cell receptor repertoire.** Abstractband zur XXI. Jahrestagung der Kind-Philipp-Stiftung für Leukämiestiftung, Wilsede, abstract 4.e, (2008)

130. H. M. Schmetzer, A. Liepert, C. Grabrucker, D. Fischbacher, M. Freudenreich, M. Merle, R. Reibke, F. Schuster, S. Reuther, A. Kremser, J. Loibl, C. Schmid, T. Kroell, A. Borkhardt, H. J. Kolb: **Leukemia-derived DC for T-cell therapy against AML progenitors.** Blood 112, 11, abstract 5442, (2008)

131. H. M. Schmetzer, A. Liepert, C. Grabrucker, D. Fischbacher, M. Merle, M. Freudenreich, F. Schuster, S. Reuther, A. Kremser, J. Loibl, R. Reibke, C. Schmid, T. Kroell, H. J. Kolb: **The composition and quality of leukemia-derived dendritic cells, T-cells and cellular microenvironment is predictive for the antileukemic T-cell cytotoxic reactions of DC-**

primed T-cells and the response to therapy. Bone Marrow Transplantation 43, suppl. 1, abstract 901, 263 (2009)

132. D. Fischbacher, M. Merle, A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, C. Schmid, T. Kroell, HJ Kolb, H. M. Schmetzer: **The composition and quality of leukemia-derived dendritic cells, T-cells and cellular microenvironment is predictive for the antileukemic T-cell cytotoxic reactions of DC-primed T-cells and the response to therapy.** Bone Marrow Transplantation 43, suppl. 1, 265, abstract 905, (2009)

134. H. M. Schmetzer, A. Liepert, C. Grabrucker, D. Fischbacher, M. Merle, M. Freudenreich, F. Schuster, S. Reuther, A. Kremser, J. Loibl, R. Reibke, C. Schmid, T. Kroell, H. J. Kolb: **The composition and quality of leukemia-derived leukemia-derived DC, T-cells and the cellular microenvironment is predictive for the antileukemic T-cell cytotoxic reactions of DC-primed T-cells and the response to therapy.** XI. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Highlight-Vortrag, 61 (2009)

135. M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, A. Kremser, J. Loibl, C. Schmid, T. Kroell, H. J. Kolb, H. M. Schmetzer: **CXCL8 and CCL2 secretion by dendritic cells generated from AML blasts (DCleu) as well as IFN gor IL6 release in mixed lymphocyte cultures (MLC) from T-cells after DC-priming are predictive for antileukemic T-cell reactions**. XI. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, 50 (2009)

136. H. J. Kolb, D. Bund, H. M. Schmetzer, C. Schmid, R. Buhmann, J. Tischer, G. Ledderose: **Longterm results nof donor lymphocyte transfusions for the treatment of relapse after allogeneic transplantation for chronic myelogenous leukemia-is there a role for immunotherapy in CML.** Blood 114, 2258 (2009)

137. H. M. Schmetzer, F. Schuster, R. Buhmann, M. Freudenreich, G. Doessinger, A. Liepert, C. Grabrucker, B. Steger, S. Reuther, A. Kremser, J. Loibl, D. Fischbacher, C. Schmid, T. Kroell, D. Busch, Borkhardt, H. J. Kolb: **Immunotherapy of AML: antileukemic effects by unprimed or primed, selected, or unselected effector T-cells.** Blood 114, 5122 (2009)

138. S. Reuther, F. Schuster, C. Grabrucker, A. Liepert, R. Reibke, T. Yang, T. Kroell, H. J. Kolb, A. Borkhardt, R. Buhmann, H. M. Schmetzer: **Characterisation of leukemia specific T-lymphocyte clones stimulated with AML-derived dendritic cells: value of spectratyping in combination with functional flow cytometry and fluorolysis analyses.** Bone Marrow Transplantation 45, suppl. 2, abstract 418, 8 (2010)

139. M. Freudenreich, C. Schmid, J. Dreyssig, A. Kremser, T. Kroell, J. Tischer, H. J. Kolb, H. M. Schmetzer: **Clinical relevance of in vitro generated dendritic cells of leukemic origin (Dcleu) in patients with AML.** Bone Marrow Transplantation 45, suppl. 2, abstract 959, 300 (2010)

140. H. M. Schmetzer, A. Liepert, C. Grabrucker, D. Fischbacher, M. Merle, R. Reibke, J. Tischer, T. Kroell, C. Schmid, H. J. Kolb: **Clinical relevance of in vitro generated dendritic cells of leukemic origin (Dcleu) in patients with AML.** Bone Marrow Transplantation 45, suppl. 2, abstract 960, 300 (2010)

142. V. Vogt, J. Schick, M. Zerwes, T. Kroell, C. Schweiger, C. Koehne, R. Buhmann, H. J. Kolb, H. M. Schmetzer: **Antileukaemic T-cell responses after DC-stimulation can be predicted by composition of T-cell subpopulations especially with respect to naive, central**

memory and non-naïve T-cells. Bone Marrow Transplantation 46, suppl. 1, abstract 1047, (2011)

143. J. Schick, V. Vogt, M. Zerwes, T. Kroell, C. Schweiger, C. Köhne, H. J. Kolb, R. Buhmann, H. M. Schmetzer: **Antileukaemic T-cell responses after dendritic cell stimulation can be predicted by compositions of regulatory T-cell subpopulations, especially with respect to regulatory central memory and regulatory CD8 cells.** Bone Marrow Transplantation 46, suppl. 1, abstract 1048, (2011)

146. H. M. Schmetzer, B. Steger, D. Bund, A. Gallo, G. Doessinger, J. Schick, V. Vogt, C. Grabrucker, A. Liepert, M. Freudenreich, S. Milosevic, J. Tischer, S. Reuther, F. Schuster, D. Busch, J. Adamski, A. Borkhardt, H. J. Kolb, C. Schmid, R. Buhmann: **The T-cells' role in anti-leukemic reactions and perspectives for future therapies of acute myeloid leukemia (AML).** XIII. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Vortrag, 55 (2011)

147. H. J. Kolb, H. M. Schmetzer A. Borkhardt: **From buffy coat to vaccination**. Vortrag beim Kongress, Dubrivnik, (September 2011)

148. V. Vogt, J. Schick, M. Zerwes, T. Kroell, C. Schweiger, H. Köhne, R. Buhmann, H. J. Kolb, H. M Schmetzer: **Antileukemic T-cell response after DC stimulation can be predicted by the composition of T-cell subpopulations: Tcm, Teff as well as by the expression of activation markers and ß integrins on T-cells**. Bone Marrow Transplantation 47, suppl. 1, abstract 882, (2012)

149. C. Ansprenger, J. Schick, V. Vogt, M. Zerwes, T. Kroell, H. J. Kolb, B. Mayr, A. Mayr, H. M. Schmetzer: **Paramunity-inducing factors have the capacity to improve DC-maturity, proportions of DCleu and early T-cell proliferation, but impair ex-vivo antileukemic functionality and therefore require thorough analyses before application in man.** Bone Marrow Transplantation 47, suppl. 1, abstract 883, (2012)

150. B. Steger, S. Milosevic, G. Doessinger, S. Reuther, A. Liepert, M. Zerwes, J. Schick, V. Vogt, F. Svchuster, T. Kroell, D. Busch, A. Borkhardt, H. J. Kolb, J. Tischer, R. Buhmann, H. M. Schmetzer: **CD4+ and CD8+ T-cell reactions against leukaemia-associated or minor histocompatibility antigens in AML patients after allogeneic SCT.** Bone Marrow Transplantation 47, suppl. 1, abstract 884, (2012)

152. J. Schick, V. Vogt, M. Zerwes, T. Kroell, C. Schweiger, C. H. Köhne, H. J. Kolb, J. Tischer, R. Buhmann, H. M. Schmetzer: **Antileukaemic T-cell responses can be predicted by compositions of regulatory T-cell subpopulations, especially with respect to regulatory effector-memory and regulatory CD8+ T-cells.** Bone Marrow Transplantation 47, suppl. 1, abstract 898, (2012)

153. J. Schick, V. Vogt, M. Zerwes, T. Kroell, C. Schweiger, C.H. Köhne, H. J. Kolb, J. Tischer, R. Buhmann, H. M. Schmetzer: **Antileukaemic T-cell responses can be predicted by compositions of regulatory T-cell subpopulations, especially with respect to regulatory effector-memory and regulatory CD8+ T-cells.** XIV. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Vortrag, 50 (2012)

155. B. Steger, S. Milosevic, G. Doessinger, S. Reuther, A. Liepert, M. Zerwes, J. Schick, V. Vogt, F. Svchuster, T. Kroell, D. Busch, A. Borkhardt, H. J. Kolb, J. Tischer, R. Buhmann, H. M.

Schmetzer: **CD4+ and CD8+ T-cell reactions against leukaemia-associated or minor histocompatibility antigens in AML patients after allogeneic SCT.** XIV. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Vortrag, 55 (2012)

156. Y. Vokac, A. Hirn-Lopez, D. Deen, T. Kroell, C. Schmid, H. J. Kolb, J. Tischer, H. M. Schmetzer: **Released soluble factors in serum or supernatants of leukemia-derived dendritic cell or mixed lymphocyte cultures are predictive for T-cells' antileukemic functionality or clinical response to immunotherapy.** Bone Marrow Transplantation 48, suppl. 2, abstract 458, (2013)

157. A. Hirn-Lopez, D. Deen, Y. Vokac, T. Kroell, D. Kraemer, F. Schuster, A. Borkhardt, C. Schmid, H. J. Kolb, J. Tischer, H. M. Schmetzer: **Role of IFN alpha in DC-cocktails for the generation of (leukemia-derived) dendritic cells from AML-blasts, the induction of antileukemic functionality of DC-stimulated T-cells and in correlation with clinical response to immunotherapy.** Bone Marrow Transplantation 48, suppl. 2, abstract 456, (2013)

158. D. Deen, A. Hirn-Lopez, Y. Vokac, T. Kroell, C.H. Koehne, H. J. Kolb, J. Tischer, H. M. Schmetzer: **Generation of leukemia-derived dendritic cells (DC/DC_{leu}) with clinically approved response modifiers from whole-blood (WB) samples from AML-patients (PTS): an ex vivo simulation of the clinical situation.** Bone Marrow Transplantation 48, suppl. 2, abstract 447, (2013)

160. S. Reuther, F.R. Schuster, P. Krell, C. Grabrucker, A. Liepert, T. Kroell, H. J. Kolb, A. Borkhardt, R. Buhmann, H. M. Schmetzer: **In vitro induced response patterns of antileukemic T-cells - characterization by spectratyping and immunophenotyping.** XV. Wissenschaftliches Symposium der Medizinischen Klinik III, Herrsching, Poster, (2013)

161. S. Reuther, P. Krell, F. R. Schuster, C. Grabrucker, A. Liepert, T. Kroell, H. J. Kolb, A. Borkhardt, R. Buhmann, H. M. Schmetzer: **In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing**. ITOC meeting, Eur J Cancer, suppl. 2, Vortrag I15/S77, 5 (2014)

163. H. M. Schmetzer, Z. Stankova, D. Deen, A. Hirn, Y. Vokac, T. Kroell, D. Bund, R. Buhmann, A. Hausmann, C. Schmid, J. Tischer: **Immunomodulation of blasts in AML-Patients (pts) with clinically approved response modifiers to improve antileukemic T-cell reactivity: an ex vivo simulation of the clinical situation.** ITOC meeting, Eur J Cancer 2, suppl. 2, P10/P19, 10 (2014)

165. Z. Stankova, D. Deen, A. Hirn, Y. Vokac, T. Kroell, D. Bund, R. Buhmann, A. Hausmann, C. Schmid, J. Tischer, H. M. Schmetzer: **Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve antileukemic T-cell reactivity: an ex vivo simulation of the clinical situation.** Bone Marrow Transplantation 49, suppl., 106 (2014)

167. D. Deen, Z. Stankova, A. Hirn, Y. Vokac, T. Kroell, D. Bund, R. Buhmann, A. Hausmann, C. Schmid, J. Tischer, H. M. Schmetzer: **Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve antileukemic T-cell reactivity: an ex vivo simulation of the clinical situation.** XVI. Wissenschaftliches Symposium der Medizinischen Klinik III, Freising, Poster, 24 (2014)

169. H. M. Schmetzer, Z. Stankova, D. Deen, A. Hirn, Y. Vokac, A. Rabe, T. Stoschek, T. Kroell, C. Wendtner, C. Schmid, J. Tischer: **Immunomodulation of blasts in AML-patients (PTS) with clinically approved response modifiers to improve antileukemic T-Cell acivity: An ex-vivo simulation of the clinical situation:** Bone Marrow Transplantation 50, suppl. 1, p 013, 123 (2015)

170. H. M. Schmetzer, Z. Stankova, D. Deen, A. Hirn, Y. Vokac, A. Rabe, T. Stoschek, T. Kroell, C. Wendtner, C. Schmid, J. Tischer: **Immunomodulation of blasts in AML-patients (PTS) with clinically approved response modifiers to improve antileukemic T-Cell acivity: An ex-vivo simulation of the clinical situation:** ITOC2-014, Eur J. Cancer 51, 5 (2015)

171. H. M. Schmetzer, Z. Stankova, D. Deen, A. Hirn, Y. Vokac, A. Rabe, T. Stoschek, T. Kroell, C. Wendtner, C. Schmid, J. Tischer: **Immunmodulaion of blasts in AML-patients (PTS) with clinically approved response modifiers to improve antileukemic T-Cell activity: An ex-vivo simulation of the clinical situation:** XVI. Wissenschaftliches Symposium der Medizinischen Klinik III, Freising, Poster, 33 (2015)

172. M. Inngjerdingen, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, C. Wendtner, J. Tischer, C. Schmid, H. M. Schmetzer**: Immunomodulation of AML-Blasts with clinically approved response modifiers improves antileukemic T-Cell reactivity ex-vivo and leads to blast-reduction in-vivo (RAT-model).** ITOC 2016, Eur J. Cancer 55, suppl. 1, 23 (2016)

173. M. Inngjerdingen, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, C. Wendtner, J. Tischer, C. Schmid, H. M. Schmetzer: **Immunomodulation of AML-Blasts with clinically approved response modifiers improves antileukemic T-Cell reactivity ex-vivo and leads to blast-reduction in-vivo (RAT-model).** Bone Marrow Transplantation 51, suppl. 1, P674, 474 (2016)

174. M. Inngjerdingen, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, C. Wendtner, J. Tischer, C. Schmid, H. M. Schmetzer: **Immunomodulation of AML-Blasts with clinically approved response modifiers improves antileukemic T-Cell reactivity ex-vivo and leads to blast-reduction in-vivo (RAT-modell).** XVIII. Wissenschaftliches Symposium der Medizinischen Klinik III, Poster, 38 (2016)

175. C. L. Boeck, D. C. Amberger, F. Doraneh-Gard, W. Sutanto, T. Guenther, J. Schmohl, F. Schuster, H. Salih, F. Babor, A. Borkhardt, H. M. Schmetzer: **Significance of frequencies, compositions and/or antileukemic activity of (DC-stimulated) invariant NKT-, NK- and CIK-cells on the outcome of patients with AML, ALL and CLL.** ITOC 2017 J., Eur J Cancer, 5 (1), 13 (2017)

176. D. C. Amberger, F. Doraneh-Gard, C.L. Boeck, C. Plett, C. Gunsilius, C. Kugler, J. Werner, J. Schmohl., D. Kraemer, B. Ismann, A. Rank, C. Schmid, H. M. Schmetzer: **A new method to generate mature (leukemia derived) dentritic cells that improve antileukemic T-cell reactivity from mononuclear ells or whole blood from healthy volunteers or patients with AML.** ITOC 2017 J., Eur J Cancer 5 (1), 4-5 (2017)

177. C. Plett, D. C. Amberger, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, J. Werner, D. Krämer, A. Rank, C. Schmid, H. M. Schmetzer: **Immunomodulatory Kits do not induce AML-blasts' proliferation ex vivo. IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts.** ITOC 2017 J. Im Eur J Cancer, 5 (1), 3-4 (2017)

178. D. C. Amberger, F. Doraneh-Gard, C. L. Boeck, C. Plett, C. Gunsilius, C. Kugler, J. Werner, J. Schmohl., D. Kraemer, B. Ismann, A. Rank, C. Schmid, H. M. Schmetzer: **A new method to generate mature (leukemia derived) dendritic cells that improve antileukemic T-cell reactivity from mononuclear cells or whole blood from healthy volunteers or patients with AML.** Bone Marrow Transplantation 43, suppl. 1, P, abstracts. (2017)

179. C. Plett, D. C. Amberger, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, J. Werner, D. Krämer, A. Rank, C. Schmid, H. M. Schmetzer: **Immunomodulatory Kits do not induce AML-blasts' proliferation ex vivo. IPO-38 is an appropriate and reliable marker to detect and qualify proliferating blasts**. EBMT 2017, Bone Marrow Transplantation 43, supp 1, P2, abstract 221 (2017)

180. Vortrag in der BioM: ImmPact Matchworking event', H. M. Schmetzer: **Immunomodulation of AML-blasts with clinically approved response modifiers improves antileukemic T-cell reactivity and leads to blast-reduction ex vivo and in vivo** (3. März 2017)

181. Vortrag im Universitätsklinikum Augsburg', H. M. Schmetzer: **Immunomodulation of AML-blasts with clinically approved response modifiers improves antileukemic t-cell reactivity and leads to blast-reduction ex vivo and in vivo** (25.4. 2017)

182. Vortrag an der MHH Hannover, H. M. Schmetzer: **Immunomodulation of AML blasts improves anti-leukemic reactivity ex vivo and in vivo** (22.12. 2017)

183. C. Schmid, M. Atzler, A. Rank, Marit Inngjerdingen, A. Rabe, D. Deen, R. Wang, B. Eiz-Vesper, H. M. Schmetzer: **Immune Modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinical approved Response Modifiers inmproves clinical status, blood cell regeneration and gives rise to leukemiaspecific adaptive and innate immune reactive cells** Poster ITOC 2018 Eur J Cancer, 92, supp1, 15 (2018)

184. F. Doraneh-Gard, D. C. Amberger, M. Weinman, C. L. Boeck, C. Gunsilius, C. Kugler, J. Werner, D. Kraemer, A. Rank, C. Schmid, H. M. Schmetzer: **Standard-normoxic versus physiological hypoxic culture of AML-patients' (pts) whole blood (wb) samples with immunomodulatory kits yields comparable proportions of dendritic cells and functional results** Poster ITOC 2018 Eur J Cancer, 92, supp1, 10-11 (2018)

185. C. Schmid, M. Atzler, A. Rank, Marit Inngjerdingen, Alex Rabe, D. Deen, R. Wang, B. Eiz-Vesper, H. M. Schmetzer: **Immune modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinical approved response modifiers improves clinical status, blood cell regeneration and gives rise to leukemia-specific adaptive and innate immune reactive cells** Poster EBMT 2018, 92, supp 1, 15 (2018)

186. F. Doraneh-Gard, D. C. Amberger, M. Weinman, C. L. Boeck, C. Gunsilius, C. Kugler, J. Werner, D. Kraemer, A. Rank, C. Schmid, H. M. Schmetzer: **Standard-normoxic versus physiological hypoxic culture of AML-patients' (pts) whole blood (WB) samples with immunomodulatory kits yields comparable proportions of dendritic cells and functional results** Poster EBMT 2018, 92, supp 1, 10-11 (2018)

187. M. Freudenreich, J. Tischer, T. Kroell, A. Kremser, J. Dreyßig, C. Grabrucker, A. Liepert, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Clinical relevance of in vitro generated dentritic cells**

of leukemic origin to predict response to immunotherapy in patients with AML and MDS. European journal of Cancer, vol 110, Supp 1, P6.06, (2019)

188. M. Atzler, A. Rank, M. Inngjerdingen, A. Rabe, D. Deen, R. Wang, B. Eiz-Vesper, C. Schmid, H. M. Schmetzer: **Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers.** European journal of Cancer, vol 110, Supp 1, P6.05, (2019)

189. Z. Fischer, D. Deen, A. Hirn, C. Plett, C. Kugler, A. Rabe, A. Liepert, M. Freudenreich, D. Kraemer, C. Schmid, H. M. Schmetzer: **Modulation of AML-blasts with clinically approved response modifiers to leukemia-derived Dendritic cells (DC_{leu}) ex vivo: DC-, T-cell- and cytokine profiles are predictive for antileukemic T-cell reactivity.** European journal of Cancer, vol 110, Supp 1, P6.03, (2019)

190. M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C. Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Conversion of aml-blasts to leukemia-derived Dendritic Cells (DCleu) in 'DC-culture-media' shifts the (serum) chemokine-release profile to a more 'inflammatory' (in culture) going along with improved antileukemic T-cell-reactivity.** European journal of Cancer, vol 110, Supp 1, P5.01, (2019)

191. M. Freudenreich, J. Tischer, T. Kroell, A. Kremser, J. Dreyßig, C. Grabrucker, A. Liepert, H. J. Kolb, C. Schmid, H. M. Schmetzer: **Clinical relevance of in vitro generated dendritic cells of leukemic origin to predict response to immunotherapy in patients with AML and MDS.** EBMT, Bone Marrow Transplantation 54, suppl. 1, P002 (2019)

192. M. Atzler, A. Rank, M. Inngjerdingen, A. Rabe, D. Deen, R. Wang, B. Eiz-Vesper, C. Schmid, H. M. Schmetzer: **Increased detection of (Leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers.** EBMT, Bone Marrow Transplantation 54, suppl. 1, P018 (2019)

193. Z. Fischer, D. Deen, A. Hirn, C. Plett, C. Kugler, A. Rabe, A. Liepert, M. Freudenreich, D. Kraemer, C. Schmid, H. M. Schmetzer: **Modulation of AML-blasts with clinically approved response modifiers to Leukemia-Derived Dendritic Cells (DC_{leu}) ex vivo: DC-, T-cell- and cytokine profiles are predictive for antileukemic T-cell reactivity.** EBMT, Bone Marrow Transplantation 54, suppl. 1, P589 (2019)

194. M. Merle, D. Fischbacher, A. Liepert, C. Grabrucker, T. Kroell, A. Kremser, J. Dreyssig, M. Freudenreich, F. Schuster, A. Borkhardt, D. Kraemer, C. H. Koehne, H. J. Kolb, C. Schmid, H. M. Schmetzer: **AML-blast conversion to leukemia-derived dendritic cells (DCLEU) in 'DC-culture-media' shifts the (SERUM) chemokine-release to a more 'inflammatory' (in culture) going along with improved antileukemic T-cell-reactivity.** EBMT, Bone Marrow Transplantation 54, suppl. 1, P069 (2019)

195. S. Ugur, L. K. Klauer, C. Blasi, F. Doraneh-Gard, C. Plett, C. Gunsilius, D. C. Amberger, M. Weinmann, O. Schutti, Z. Fischer, E. Özkaya, M. Atzler, E. Pepeldjiyska, A. Völker, J. Schmohl, A. Rank, C. Schmid, H. M. Schmetzer: **'Kit'-mediated blastmodulation to leukemia-derived DC significantly improves antileukemic activities in whole blood independent of AML-patients' subtypes.** EBMT, Bone Marrow Transplantation (2020)

196. C. Kugler, D. Deen, D. Amberger, Z. Fischer, F. Dorenah-Gard, C. Gunsilius, A. Hirn, T. Kroell, J. Tischer, M. Weinmann, U. Ködel, J. Werner, A. Rank, C. Schmid, H. M. Schmetzer **Immunomodulation of blasts with clinically approved response modifiers to improve antileukemic T-cell reactivity in AML: an ex vivo simulation of the clinical situation.** EBMT, Bone Marrow Transplantation (2020)

197. L. Li, V Mussack, E. Pepeldjiyska, A. Hartz, A. Rank, C. Schmid, E. Özkaya, S. Ugur, M. Pfaffl, H. M. Schmetzer: P01.11 **Role of exosomes as promotors or biomarkers to study activation of leukemia-derived dendritic cells (DCleu)-mediated antileukemic activation of adaptive and innate immune-reactive cells against AML-blasts**. EBMT, Bone Marrow Transplantation 54, suppl. 1, A392 (2020)

198. L. K. Klauer, O. Schutti, S. Ugur, F. Doraneh-Gard, N. Rogers, M. Weinmann, D. Krämer, A. Rank, C. Schmid, B. Eiz-Vesper, H. M. Schmetzer: **IFNy secretion of adaptive and innate immune cells as a parameter to display leukaemia derived dendritic cell (DC_{leu}) mediated immune responses in AML.** EBMT, Bone Marrow Transplantation, A396 (2020)

199. W. Biehl, A. Hattesohl, R. Jörres, T. Duell, U. Althöhn**,** R. Koczulla, H. M. Schmetzer: **VOC-pattern recognition of lung cancer: a comparative evaluation of different dog- and enose-based strategies using different sampling materials.** EBMT, Bone Marrow Transplantation (2020)

200. L. Li, V Mussack, E Pepeldjiyska, A Hartz, A Rank, C Schmid, E Özkaya, S Ugur, M Pfaffl, H. M. Schmetzer: **Role of exosomes as promotors or biomarkers to study activation of leukemia-derived dendritic cells (DCleu)-mediated antileukemic activation of adaptive and innate immune-reactive cells against AML-blasts**. P01.11 Journal for ImmunoTherapy of Cancer Oct 2020, 8 (Suppl 2) A13-A14; DOI: 10.1136/jitc-2020-ITOC7.24 (2020)

201. L. K. Klauer, O. Schutti, S. Ugur, F. Doraneh-Gard, N. Rogers, M. Weinmann, D. Krämer, A. Rank, C. Schmid, B. Eiz-Vesper, H. M. Schmetzer: P01.10 **IFNy secretion of adaptive and innate immune cells as a parameter to display leukaemia derived dendritic cell (DCleu) mediated immune responses in AML**. Journal for ImmunoTherapy of Cancer Oct 2020, 8 (Suppl 2) A13; doi: 10.1136/jitc-2020-ITOC7.23 (2020)

202. W. Biehl, H. M. Schmetzer, R. Koczulla, A. Hattesohl, R. Jörres, T. Duell, U. Althöhn: **VOC pattern recognition of lung cancer: a comparative evaluation of different dog- and eNose-based strategies using different sampling materials**. P01.03 Journal for ImmunoTherapy of Cancer Oct 2020, 8 (Suppl 2) A9; doi: 10.1136/jitc-2020-ITOC7.16 (2020)

203. C. Kugler, D. Deen, D. Amberger, Z. Fischer, F. Dorenah-Gard, C. Gunsilius, A. Hirn, T. Kroell, J. Tischer, M. Weinmann, U. Ködel, J. Werner, A. Rank, C. Schmid, H. M. Schmetzer **Immunomodulation of blasts with clinically approved response modifiers to improve antileukemic T-cell reactivity in AML: an ex vivo simulation of the clinical situation.** Journal for ImmunoTherapy of Cancer Oct 2020, 8 (Suppl 2) A7; doi: 10.1136/jitc-2020-ITOC7 (2020)

204. S. Ugur, L. K. Klauer, C. Blasi, F. Doraneh-Gard, C. Plett, C. Gunsilius, D. C. Amberger, M. Weinmann, O. Schutti, Z. Fischer, E. Özkaya, M. Atzler, E. Pepeldjiyska, A. Völker, J. Schmohl, A. Rank, C. Schmid, H. M. Schmetzer: **'Kit'-mediated blastmodulation to leukemia-derived DC significantly improves antileukemic activities in whole blood independent of AML-**

patients' subtypes. Journal for ImmunoTherapy of Cancer Oct 2020, 8 (Suppl 2) A6; doi: 10.1136/jitc-2020-ITOC7 (2020)

205. H. M. Schmetzer D. Amberger, L. Klauer, E. Rackl, M. Atzler, S. Ugur, C. Plett, A. Rabe, C. Kugler, A. Rank, M. Inngjerdingen. T. Baudrexler, B. Eiz-Vesper, C. Schmid: **Control leukemia by inducing anti-cancer immune reactivity in vivo: potential of a DC-triggered** mechanism, ebmt online (2021)

206. S. Bohlscheid, G. Filippini Velazquez, T. Baudrexler, H. Aslan, M. Trepel, C. Schmid, H. M. Schmetzer**: Aberrant expressions of Checkpoints on AML blasts and T-Cells result in downregulation of immune responses in patients relapsing after allogenic stem cell transplantation**, ebmt online (2021)

207. L. Li, V. Mussack, A. Görgens, E. Pepeldjiyska, A. S. Hartz, H. Aslan, E. Rackl, A. Rank, J. Schmohl, M. W. Pfaffl, H. M. Schmetzer: **The potential role of extracellular vesicle derived small RNAs in AML research as non-invasive** biomarker, ebmt online, (2021)

208. H. M. Schmetzer D. Amberger, L. Klauer, E. Rackl, M. Atzler, S. Ugur, C. Plett, A. Rabe, C. Kugler, A. Rank, M. Inngjerdingen. T. Baudrexler, B. Eiz-Vesper, C. Schmid: **Control leukemia by inducing anti-cancer immune reactivity in vivo: potential of a DC-triggered mechanism**, itoc munich ejc (2022)

209. H. M. Schmetzer D. Amberger, L. Klauer, E. Rackl, M. Atzler, S. Ugur, C. Plett, A. Rabe, C. Kugler, A. Rank, M. Inngjerdingen. T. Baudrexler, B. Eiz-Vesper, C. Schmid: **Control leukemia by inducing anti-cancer immune reactivity in vivo: potential of a DC-triggered mechanism**, ebmt online (2022)

210. G. Philippini, D. Amberger, L. Klauer, E. Rackl, M. Atzler, S. Ugur, C. Plett, A. Rabe, C. Kugler, A. Rank, M. Inngjerdingen. T. Baudrexler, B. Eiz-Vesper, C. Schmid, H. M. Schmetzer: P475**: Control leukemia by inducing anti-cancer immune reactivity in vivo? potential of a DC-triggered mechanism**. HemaSphere, 6:374-5 (2022)

211. S. Bohlscheid, G. Filippini Velazquez T. Baudrexler, H. Aslan, M. Trepel, C. Schmid, H. M. Schmetzer: **Dysregulated expressions of inhibitory checkpoint molecules and their ligands on T-cells and blasts in AML relapses after stem cell transplantation (sct**). HemaSphere, 6:1194-5 (2022)

212. S. Bohlscheid, G. Velazquez, H. Aslan, T. Baudrexler, H. M. Schmetzer, C. Schmid: **Dysregulated expressions of inhibitory checkpoint molecules and their ligands on t-cells and blasts in AML relapses after stem cell transplantation (sct)**. P1309: J. Immunotherapy of cancer 10: (supp1),10.1136/jitc-2022-ITOC9.66 (2022)

213. T. Baudrexler, T. Boeselt, S. Bohlscheid, L. Li, C. Schmid, A. Rank, J. Schmohl, H. M. Schmetzer: **Volatile profiling using an eNose allows differentiation of volatile phases derived from serum, DC, or MLC culture supernatants from healthy or leukemic samples**: J. Immunotherapy of cancer 10:(supp1),10.1136/jitc-2022-ITOC9.37 (2022)

214. L. Li, V. Mussack, A. Goergens, E. Pepeldjiyska, A. Hartz, H. Aslan, E. Rackl, A. Rank, J. Schmohl, M. Pfaffl, H. M. Schmetzer: (Germany) **The potential Role of Extracellular Vesicle derived small RNAs in AML research as non invasive biomarker** J. Immunotherapy of cancer 10: (supp1),10.1136/jitc-2022-ITOC9.45 (2022)

215. H. M. Schmetzer, D. Amberger, L. Klauer, E. Rackl, M. Atzler, S. Ugur, C. Plett, A. Rabe, C. Kugler, A. Rank, M. Inngjerdingen. T. Baudrexler, B. Eiz-Vesper, C. Schmid: **Control leukemia by inducing anti-cancer immune reactivity in vivo: potential of a DC-triggered mechanism** J. Immunotherapy of cancer 10: (supp1),10.1136/jitc-2022-ITOC9.46 (2022)